Table 5 National Paediatric Rheumatological Database (NPRD) with a uveitis add-on module in Germany (2002–2016). Initial uveitis documentation: anti-inflammatory treatment in previous 12 months. Data as provided in NPDR and/or uveitis documentation
Initial documentation. Anti-inflammatory treatment in previous 12 months | Group I. Uveitis, ANA-positive, no JIA, N = 62 | Group II. Uveitis manifestation after JIA disease onset*, N = 668 | Group III. Uveitis manifestation before JIA disease onset*, N = 61 | p value†| Significant pairwise comparisons‡ | |||
|---|---|---|---|---|---|---|---|---|
|  | Treatment | Uveitis inactivity‡‡ | Treatment | Uveitis inactivity‡‡ | Treatment | Uveitis inactivity‡‡ |  |  |
Any DMARD, n (%) | 31 (52.5%) | 2 (9.5%) | 424 (65.6%) | 63 (28.0%) | 42 (70.0%) | 1 (6.7%) | 0.091 | – |
Methotrexate, n (%) | 27 (45.8%) | 1 (5.3%) | 382 (59.1%) | 59 (29.1%) | 40 (66.7%) | 1 (7.1%) | 0.058 | I vs. III |
Adalimumab, n (%) | 5 (8.5%) | 1 (20.0%) | 41 (6.4%) | 8 (26.7%) | 4 (6.7%) | 0 (0.0%) | 0.817 | – |
Systemic corticosteroids, n (%) | 18 (29.0%) | 1 (10.0%) | 128 (19.3%) | 22 (35.5%) | 16 (26.2%) | 1 (25.0%) | 0.108 | – |
Topical corticosteroids, n (%) | 36 (58.1%) | 5 (19.2%) | 388 (58.2%) | 53 (23.5%) | 37 (60.7%) | 1 (8.3%) | 0.930 | – |